tetano
Editor, Senior Moderator
Infect Chemother
. 2024 Dec;56(4):453-460.
doi: 10.3947/ic.2024.0142. COVID-19 Vaccination Recommendations for 2024-2025 in Korea
Wan Beom Park[SUP] 1 [/SUP], Young Hoon Hwang[SUP] 2 [/SUP], Ki Tae Kwon[SUP] 3 [/SUP], Ji Yun Noh[SUP] 4 [/SUP], Sun Hee Park[SUP] 5 [/SUP], Joon Young Song[SUP] 4 [/SUP], Eun Ju Choo[SUP] 6 [/SUP], Min Joo Choi[SUP] 7 [/SUP], Jun Yong Choi[SUP] 8 [/SUP], Jung Yeon Heo[SUP] 9 [/SUP], Won Suk Choi[SUP] 4 [/SUP]; Committee on Adult Immunization of the Korean Society of Infectious Diseases
Affiliations
The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024-2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.
Keywords: COVID-19; SARS-CoV-2; Vaccination.
. 2024 Dec;56(4):453-460.
doi: 10.3947/ic.2024.0142. COVID-19 Vaccination Recommendations for 2024-2025 in Korea
Wan Beom Park[SUP] 1 [/SUP], Young Hoon Hwang[SUP] 2 [/SUP], Ki Tae Kwon[SUP] 3 [/SUP], Ji Yun Noh[SUP] 4 [/SUP], Sun Hee Park[SUP] 5 [/SUP], Joon Young Song[SUP] 4 [/SUP], Eun Ju Choo[SUP] 6 [/SUP], Min Joo Choi[SUP] 7 [/SUP], Jun Yong Choi[SUP] 8 [/SUP], Jung Yeon Heo[SUP] 9 [/SUP], Won Suk Choi[SUP] 4 [/SUP]; Committee on Adult Immunization of the Korean Society of Infectious Diseases
Affiliations
- PMID: 39762924
- DOI: 10.3947/ic.2024.0142
The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024-2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.
Keywords: COVID-19; SARS-CoV-2; Vaccination.